Navigation Links
Marshall Edwards Announces Closing of Asset Purchase Agreement With Novogen
Date:5/10/2011

he first patient is enrolled in a Phase III clinical trial, each share of Class A Preferred Stock not already converted will become convertible into 9,654 of Marshall Edwards common stock.

About Marshall Edwards

Marshall Edwards, Inc. (Nasdaq: MSHL) is a San Diego-based oncology company focused on the clinical development of novel anti-cancer therapeutics. The Company's lead programs focus on two families of small molecules that result in the inhibition of tumor cell metabolism. The first and most advanced is a NADH oxidase inhibitor program that includes lead drug candidate NV-143. The second is a mitochondrial inhibitor program that includes NV-128 and its next-generation candidate NV-344. Both programs are expected to advance into the clinic in 2011. For more information, please visit www.marshalledwardsinc.com.

Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those contained in the forward-looking statements, which are based on Novogen's and Marshall Edwards' management's current expectations and are subject to a number of risks and uncertainties, including, but not limited to, the ability of the parties to obtain all necessary approvals for the proposed transaction or the failure to consummate, or a delay in consummating, the transaction for other reasons; costs and delays in the development and/or FDA approval, or the failure to obtain such approval, of product candidates; uncertainties or differences in interpretation in clinical trial results; the parties' inability to maintain or enter into, and the risks resulting from dependence upon, collaboration or contractual arrangements necessary fo
'/>"/>

SOURCE Marshall Edwards, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Marshall Edwards Announces Private Placement
2. Marshall Edwards Announces Publication of Phase II Clinical Trial Results Highlighting Activity of Intravenous Phenoxodiol
3. Marshall Edwards Receives Positive Response From NASDAQ
4. Marshall Edwards to Host Annual Meeting of Stockholders
5. Marshall Edwards Receives NASDAQ Notice Of Non-Compliance; Intends To Request Hearing
6. Marshall Edwards Announces Presentation of New Data Showing Activity in Chemotherapy-Resistant Ovarian Cancer Cells
7. Edwards Lifesciences Announces First Implants in U.S. Study of Minimally-Invasive Pulmonic Valve
8. Edwards Resilient Trial Demonstrates Statistically Superior Results for Treating Peripheral Arterial Disease in the Leg
9. Pfenex Announces Strategic Collaboration With MedImmune for the Use of Pfenex Expression Technology™
10. Insmed Announces First Quarter 2011 Financial Results
11. Intercell AG Announces Q1 2011 Results and Updates on R&D Progress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... Asterias Biotherapeutics, Inc. (OTCBB: ASTY), a leading ... announced today the appointments of Andrew ("Andy") Arno and ... of Directors. With these additions, the Asterias Board of ... independent. Andy Arno , 55, has ... He is currently Managing Director of Emerging Growth Equities, ...
(Date:8/20/2014)... , Aug. 20, 2014 The ... lauded the latest results achieved by the real-time, ... as the National Precursor Log Exchange (NPLEx), automatically ... officials track down meth offenders and make arrests. ... Kansas blocked the sale ...
(Date:8/20/2014)... , Aug. 20, 2014 Reportlinker.com announces ... in its catalogue: The Impact of ... http://www.reportlinker.com/p01618927/The-Impact-of-Healthcare-Reform-PPACA-On-the-US-IVD-Industry.html ... 3590) is complex legislation that affects virtually every ... provisions are beginning to take effect now. IVD ...
Breaking Medicine Technology:Asterias Biotherapeutics Appoints Two Independent Directors and Announces Completion of Series A Common Stock Distribution 2Asterias Biotherapeutics Appoints Two Independent Directors and Announces Completion of Series A Common Stock Distribution 3Asterias Biotherapeutics Appoints Two Independent Directors and Announces Completion of Series A Common Stock Distribution 4Kansas's Stop-Sale System Achieves Significant Results In Battle Against Meth 2The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry 2The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry 3The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry 4The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry 5The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry 6
... Solutions, Inc. (Allscripts – NASDAQ: MDRX ) ... Paul M. Black, former Chief Operating Officer of Cerner ... Senior Vice President and Chief Legal Officer for the ... immediately.  Mr. Black will serve on the Board,s Compensation ...
... Hours, or even minutes, can mean the difference between life ... of Emergency Medical Services (EMS) Week from May ... about how quick recognition of stroke symptoms and timely response ... return to full health. Stroke is the ...
Cached Medicine Technology:Allscripts Adds Two Independent Directors to Board 2Allscripts Adds Two Independent Directors to Board 3Allscripts Adds Two Independent Directors to Board 4Allscripts Adds Two Independent Directors to Board 5"Emergency Medical Services Week" Highlights Stroke Survivors and Awareness 2"Emergency Medical Services Week" Highlights Stroke Survivors and Awareness 3"Emergency Medical Services Week" Highlights Stroke Survivors and Awareness 4"Emergency Medical Services Week" Highlights Stroke Survivors and Awareness 5
(Date:8/21/2014)... HealthDay Reporter THURSDAY, Aug. 21, 2014 (HealthDay ... nearly 12 percent in the last decade, a new report ... teens using indoor tanning beds barely decreased. Both indoor tanning ... cancers, including deadly melanomas, the researchers noted. "Unfortunately, we ... reported wearing sunscreen, from 67.7 percent in 2001 to 56.1 ...
(Date:8/21/2014)... Orange, NJ. August 21, 2014. Researchers have published ... the outcomes of patients with motor complete spinal ... disparities in functioning at discharge and follow-up among ... ahead of print on August 2 by the ... (doi: 10.1016/j.apmr.2014.07.398). Findings included small but significant differences ...
(Date:8/21/2014)... 2014 CarePoint Health is proud ... Patel, MD, and Sujoy Menon, MD, have joined ... and Dr. Menon to the community. CarePoint Health’s ... imaging services to patients in Hudson County through ... Hospital and Hoboken University Medical Center. Our board ...
(Date:8/21/2014)... August 21, 2014 The Mount Sinai ... tool called RateMyHospital®, which captures real-time patient feedback and ... patient’s care. The tool, now available to admitted patients ... collects feedback regarding patient satisfaction using smartphones. , ... because it gives us the timely information we need ...
(Date:8/21/2014)... New York (PRWEB) August 21, 2014 ... Cannabis Network that a company located in Massachusetts has ... the only marijuana patient verification system in ... welcome this new entity to our growing and compassionate ... our belief that these claims are inaccurate. , ...
Breaking Medicine News(10 mins):Health News:Fewer U.S. Teens Using Sunscreen, Study Finds 2Health News:Researchers examine impact of race and ethnicity in motor complete spinal cord injury 2Health News:Two Top Radiologists Join CarePoint Health 2Health News:The Mount Sinai Hospital Expands Use of Mobile Patient Satisfaction Tool 2Health News:The Mount Sinai Hospital Expands Use of Mobile Patient Satisfaction Tool 3Health News:MarijuanaDoctors.com Responds to Massachusetts Company's Claim 2
... TOWNSHIP, Mich., Jan. 27 Financing has become a,very popular ... decade.,But long after you have had your "nip and tuck", ... looking for ways to get out of debt, and at ... surgery. , Dr. Charles Mok ...
... system chosen needs to match needs, culture of staff , , ... hospital is, the lower its rate of patient deaths and ... also saves centers money, the researchers report. , Although there ... Herrick, senior fellow at the National Center for Policy Analysis ...
... for the prevention of coronary heart disease, with ... at highest risk (ie, those with established heart ... estimation models may not be accurately achieved in ... groups whose 10-year "short-term" estimated risk seems low. ...
... Participants Control Weight Permanently , MIDLAND, Mich., Jan. 27 ... term is the challenge. With this Health Enhancement Systems ... NutriSum: Healthy Weight for Life ( ... to gain control of their weight -- and improve their ...
... Create SolutionsPITTSBURGH, Jan. 27 To ... and consultants, HM Insurance Group, a Highmark company, ... product line, which features dedicated worksite sales specialists, ... and membership management in a highly coordinated approach ...
... One in eight physicians have been inactive in the ... and most states do not require them to undergo competency ... , Because of the lack of regulation, patient safety could ... of Michigan Child Health Evaluation and Research (CHEAR) Unit and ...
Cached Medicine News:Health News:Lay Away Plan for Cosmetic Surgery 2Health News:'Wired' Hospitals Post Lower Death, Complication Rates 2Health News:'Wired' Hospitals Post Lower Death, Complication Rates 3Health News:Assessing the real risk of heart disease in young people with low short-term risks 2Health News:Thousands Look Better, Feel Better, and Have More Energy Because of NutriSum 2Health News:HM Insurance Group Launches Next Generation Worksite Product Line 2Health News:HM Insurance Group Launches Next Generation Worksite Product Line 3Health News:Most inactive physicians retain licenses, return to practice without competency review 2
The AMY method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of amylase activity in serum, plasma and urine....
The GLU method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of glucose in serum, plasma, urine and cerebrospinal fluid....
Enzymatic Clearance assay for the in vitro quantitative determination of LDL-cholesterol in human serum and plasma....
For the quantitative in vitro determination of Lipase in human serum and plasma....
Medicine Products: